Abstract:
The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (i) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomyalgia; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; and (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
Y
Y
Y
Y


US 6,498,009 B1 (Liggett) 24 December 2002 (24 12 2002), Abstract, Table 1, and coM7 in 63 - col 18 in 4

US 2004/0005306 A1 (Loscalzo et al.) 08 January 2004 (08 01 2004), para [0189]

"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure" Taylor et al., New England Journal of Medicine, Nov 2004 v351 p2049, p2051, left col in 26-35, Table 2

"Promoter polymorphism in the nitric oxide synthase 3 gene are associated with ischemic stroke susceptibility in young black women" Howard et al., Stroke Sept 2005 v36 p1848-1849, Abstract, Table 2

"Associations between aldosterone synthase (CYP1B2) gene polymorphisms and left ventricular size, mass, and function" Kupari et al., Circulation 1998 v97 p569, Abstract, Fig 2

Y

Further documents are listed in the continuation of Box C

T

Date of the actual completion of the international search
05 April 2007 (05 04 2007)

Date of mailing of the international search report
03 AUG imi

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No 571-273-3201

Authorized officer
Lee W Young

PCT HelpDesk 571 272-4300
PCTOIS 571 272-7774

Form PCT/ISA/210 (second sheet) (April 2005)
1 With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:

a type of material
   - a sequence listing
   - table(s) related to the sequence listing

b format of material
   - on paper
   - in electronic form

c time of filing/finishing
   - contained in the international application as filed
   - filed together with the international application in electronic form
   - furnished subsequently to this Authority for the purposes of search

2 In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3 Additional comments